Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To evaluate the diagnostic value of serum osteocalcin in the detection of bone metastases from differentiated thyroid carcinoma (DTC).
Design And Methods: Serum samples from DTC patients with (DTC BM+, n=19) or without bone metastases (DTC BM-, n=19), and matched healthy volunteers (n=30) were tested for serum osteocalcin with electrochemiluminescent immunoassay.
Results: Osteocalcin was higher in DTC BM+ than in DTC BM- patients (+35.8%, p=0.002), acting as an independent risk factor for bone metastases (R(2)=0.142, p=0.039). The sensitivity was 78.9% and the specificity was 63.2% at a cut-off value of 11.2 microg/L.
Conclusions: Serial measurements of osteocalcin could be useful in the detection of bone metastases from DTC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinbiochem.2009.08.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Teleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group (COSS).
Cancer Med
September 2025
Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
Purpose: Teleangiectatic osteosarcoma is a histologic subtype of osteosarcoma that can mimic aneurysmal bone cysts and has so far been incompletely characterized.
Patients And Methods: We used the database of the Cooperative Osteosarcoma Study Group COSS (patient-registration 1980-2019) to better understand this rare histologic variant.
Results: 223 eligible patients were identified, 164 having reference pathology (median age 15.
Reply to: "Beyond 1 Month: A Broader Look at the ROBOMET Trial Results" and "ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?".
J Clin Oncol
September 2025
Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Networ
ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?
J Clin Oncol
September 2025
Xingpeng Luo, MD, Bin Li, MD, and Yinglong Xi, MD, Orthopedic Treatment Center, Southern Central Hospital of Yunnan Province (The First People's Hospital of Honghe State), Mengzi City, China; and Zhixiang Chen, MD, Department of Nephrology, Southern Central Hospital of Yunnan Province (The First Peo
CLINICAL PRESENTATION OF BONE METASTASES IN NEUROENDOCRINE TUMORS: A RETROSPECTIVE COHORT STUDY.
Endocr Relat Cancer
September 2025
Endocrinology, Diabetology and Medical Andrology Unit, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy.
Bone metastases (BMs) are rare and late event in patients with neuroendocrine tumors (NETs). The aim of our study was to investigate clinical presentation and outcome of BMs in a large cohort of patients with NETs. A retrospective study was performed at two referral centers of Northern Italy (IRCCS Humanitas Research Hospital in Milan and S.
View Article and Find Full Text PDFPractice Patterns of Palliative Radiotherapy for Advanced Cancer at a Large Institute in Saudi Arabia.
Palliat Med Rep
April 2025
Department of Oncology, King Faisal Specialist Hospital & Research Centre (KFSH&RC), Jeddah, Saudi Arabia.
Background And Aims: Palliative radiotherapy practice patterns have been reported to vary widely, with a notable underutilization of single fraction treatment schedules. This study aims to investigate the outcomes and care patterns among patients receiving palliative radiotherapy for advanced cancer at a high-volume institution in Saudi Arabia.
Materials And Methods: Electronic records were used to identify patients receiving palliative radiotherapy for advanced cancer between 2018 and 2023.